Prospects for redox-based therapy in neurodegenerative diseases

[1]  Jong-Hwa Lee,et al.  Inhibition of neuronal nitric oxide synthase by antipsychotic drugs , 1994, Psychopharmacology.

[2]  J S Beckman,et al.  Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. , 1999, Science.

[3]  R. L. Russell,et al.  Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. , 1999, Archives of biochemistry and biophysics.

[4]  P. Mecocci,et al.  Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex , 1999, Neuroscience Letters.

[5]  M. Reinholz,et al.  Therapeutic Benefits of Putrescine-Modified Catalase in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1999, Experimental Neurology.

[6]  N. Holbrook,et al.  Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. , 1999, Neuroreport.

[7]  H. Tohgi,et al.  Remarkable increase in cerebrospinal fluid 3‐nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis , 1999, Annals of neurology.

[8]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[9]  George Perry,et al.  RNA Oxidation Is a Prominent Feature of Vulnerable Neurons in Alzheimer’s Disease , 1999, The Journal of Neuroscience.

[10]  T. Montine,et al.  Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease , 1999, Neurology.

[11]  A. Schapira,et al.  Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. , 1999, Biochimica et biophysica acta.

[12]  S. Kish,et al.  Decreased Brain Protein Levels of Cytochrome Oxidase Subunits in Alzheimer's Disease and in Hereditary Spinocerebella Ataxia Disorders , 1999, Journal of neurochemistry.

[13]  T. Montine,et al.  Increased CSF F2-isoprostane concentration in probable AD , 1999, Neurology.

[14]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.

[15]  R. Swerdlow,et al.  Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family , 1998, Annals of neurology.

[16]  M. Gurney,et al.  Protein Oxidative Damage in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1998, Journal of neurochemistry.

[17]  J. Kaye,et al.  The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. , 1998, Archives of neurology.

[18]  T. Montine,et al.  Cerebrospinal fluid F2‐isoprostane levels are increased in Alzheimer's disease , 1998, Annals of neurology.

[19]  M. Beal,et al.  Azulenyl Nitrone Spin Traps Protect against MPTP Neurotoxicity , 1998, Experimental Neurology.

[20]  E. Shoubridge,et al.  Cybrids in Alzheimer's disease: A cellular model of the disease? , 1998, Neurology.

[21]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[22]  D. Perl,et al.  Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.

[23]  P. Fürst,et al.  Glyceraldehyde-3-phosphate Dehydrogenase, the Putative Target of the Antiapoptotic Compounds CGP 3466 andR-(−)-Deprenyl* , 1998, The Journal of Biological Chemistry.

[24]  E. Stopa,et al.  Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.

[25]  B. Hyman,et al.  MPP+Induced Substantia Nigra Degeneration Is Attenuated in nNOS Knockout Mice , 1997, Neurobiology of Disease.

[26]  J. Glowinski,et al.  Pyruvate Protects Neurons against Hydrogen Peroxide-Induced Toxicity , 1997, The Journal of Neuroscience.

[27]  R. Davis,et al.  Cybrids in Alzheimer's disease: A cellular model of the disease? , 1997, Neurology.

[28]  Robert H. Brown,et al.  Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.

[29]  G. Perry,et al.  Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Gurney,et al.  Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation , 1997, Annals of neurology.

[31]  D. Price,et al.  Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Beal,et al.  Iodoacetate Produces Striatal Excitotoxic Lesions , 1997, Journal of neurochemistry.

[33]  N. Hattori,et al.  An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease , 1997, Journal of the Neurological Sciences.

[34]  Mark A. Smith,et al.  4‐Hydroxynonenal‐Derived Advanced Lipid Peroxidation End Products Are Increased in Alzheimer's Disease , 1997, Journal of neurochemistry.

[35]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[36]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[37]  Joseph S. Beckman,et al.  Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[38]  M. Beal,et al.  S-Methylthiocitrulline, a Neuronal Nitric Oxide Synthase Inhibitor, Protects against Malonate and MPTP Neurotoxicity , 1997, Experimental Neurology.

[39]  B. Rosen,et al.  Energy metabolism defects in Huntington's disease and effects of coenzyme Q10 , 1997, Annals of neurology.

[40]  H. Masumoto,et al.  Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite. , 1997, Advances in pharmacology.

[41]  L. Ellerby,et al.  Mutations in copper-zinc superoxide dismutase that cause amyotrophic lateral sclerosis alter the zinc binding site and the redox behavior of the protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[42]  M. Beal,et al.  Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.

[43]  M. Beal,et al.  Oxidative damage in Alzheimer's , 1996, Nature.

[44]  D. Perl,et al.  Evidence of neuronal oxidative damage in Alzheimer's disease. , 1996, The American journal of pathology.

[45]  E. Stadtman,et al.  A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: An enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[46]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Bredesen,et al.  Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.

[49]  P. Ince,et al.  Oxidative damage to protein in sporadic motor neuron disease spinal cord , 1995, Annals of neurology.

[50]  R N Kalaria,et al.  Induction of Heme Oxygenase‐1 mRNA and Protein in Neocortex and Cerebral Vessels in Alzheimer's Disease , 1995, Journal of neurochemistry.

[51]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  S. Zierz,et al.  Cytochrome c oxidase in Alzheimer's disease , 1995, Neurology.

[53]  Mark A. Smith,et al.  Carbonyl‐Related Posttranslational Modification of Neurofilament Protein in the Neurofibrillary Pathology of Alzheimer's Disease , 1995, Journal of neurochemistry.

[54]  P. Chagnon,et al.  Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. , 1995, Neuroreport.

[55]  J. Parks,et al.  Cytochrome C Oxidase in Alzheimer's Disease Brain , 1995, Neurology.

[56]  J. Schulz,et al.  Inhibition of Neuronal Nitric Oxide Synthase by 7‐Nitroindazole Protects Against MPTP‐Induced Neurotoxicity in Mice , 1995, Journal of neurochemistry.

[57]  P. Yu,et al.  Pharmacological and clinical implications of MAO-B inhibitors. , 1994, General pharmacology.

[58]  M. Beal,et al.  Cortical Cytochrome Oxidase Activity Is Reduced in Alzheimer's Disease , 1994, Journal of neurochemistry.

[59]  Patrizia Mecocci,et al.  Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease , 1994, Annals of neurology.

[60]  G. Perry,et al.  Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. , 1994, The American journal of pathology.

[61]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Snyder,et al.  Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.

[63]  B. Rosen,et al.  Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy , 1993, Neurology.

[64]  Robert H. Brown,et al.  Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis , 1993, Journal of neurochemistry.

[65]  C. Rice-Evans,et al.  Current status of antioxidant therapy. , 1993, Free radical biology & medicine.

[66]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[67]  C. Olanow.  A rationale for monoamine oxidase inhibition as neuroprotective therapy for parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.

[68]  B R Rosen,et al.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. , 1993, Neurology.

[69]  R. S. Sohal,et al.  Age-related changes in antioxidant enzymes and prooxidant generation in tissues of the rat with special reference to parameters in two insect species. , 1990, Free radical biology & medicine.

[70]  P. Stacpoole.  The pharmacology of dichloroacetate. , 1989, Metabolism: clinical and experimental.

[71]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[72]  J. B. Martin,et al.  Selective sparing of a class of striatal neurons in Huntington's disease. , 1985, Science.

[73]  S. Skaper,et al.  Pyruvate participation in the low molecular weight trophic activity for central nervous system neurons in glia-conditioned media , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[74]  Diana Brahams,et al.  Medicine and the Law , 1983, The Lancet.

[75]  A. Azzi.  Cytochrome c oxidase. Towards a clarification of its structure, interactions and mechanism. , 1980, Biochimica et biophysica acta.

[76]  A. Szent-Györgyi.  On Oxidation, Fermentation, Vitamins, Health And Disease , 1940 .